Perrigo Expects Settlement To Lower Irish Tax Debt
Executive Summary
Ireland’s Office of Revenue concluded it “would not object if the Tax Appeals Commission adjusted the amount of the assessment to less than €1 billion,” says Perrigo CEO Murray Kessler.
You may also be interested in...
Who You Gonna Call For US Oral Contraceptive Switch? Former FDA Official Heads Perrigo Americas
Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.
Perrigo Paying $309M To Settle $1.9Bn Irish Tax Assessment From Elan Merger
OTC private label/store brand giant announces Irish authorities allow it to pay $308.7m to settle a $1.9bn assessment for back taxes ordered in 2018 linked to Rx ingredient royalty rights it gained in its 2103 merger with Elan.
Perrigo Expects Trans-Atlantic Boost: Eliminating Irish Tax Debt, Importing European Brands
In investor conference presentations, CEO Kessler says “we have a very strong case that the way we filed those taxes was correctly and the assessment should be 0,” and bringing its European consumer health brands to the US is “finally starting to really happen.”